RESUMO
Umbilical endometriosis is a rare manifestation, most often isolated, of endometriosis, accounting for 0,5-1 % of all cases. It can be primary or secondary following surgery. It usually presents as a solid, skin-colored, red or purple-black nodule, frequently associated with pain and/or perimenstrual bleeding. Because it has a potential for malignant transformation, the gold standard of treatment is surgical removal.
L'endométriose ombilicale, ou nodule de Villar, est une manifestation rare et le plus souvent isolée d'endométriose, survenant dans 0,5 à 1 % des cas. Elle peut être primaire ou secondaire à une intervention chirurgicale. Elle se manifeste habituellement par un nodule ferme, de couleur chair, rouge ou violet-noir, fréquemment associé à des douleurs et/ou des saignements péri-menstruels. Il existe un risque potentiel de transformation maligne, raison pour laquelle le traitement de première intention est l'exérèse chirurgicale.
Assuntos
Endometriose , Feminino , Humanos , Endometriose/diagnóstico , Endometriose/cirurgia , Endometriose/patologia , Umbigo/patologia , Umbigo/cirurgia , Dor , Pele/patologia , HemorragiaRESUMO
BRAF inhibitors may present several cutaneous adverse effects, including actinic keratosis, squamous cell carcinoma, keratoacanthoma, rashes, increased photosensitivity, panniculitis, palmoplantar and capillary involvement, pruritus and xerosis as well as granulomatous reactions. A 30-year-old patient with multiple tattoos received dabrafenib and trametinib for metastatic melanoma. After 4 months, he developed an induration and thickening strictly limited to several tattoos. Histopathology revealed nonnecrotizing granulomas in the dermis. Topical steroids relieved pruritus but not the granulomatous aspect of the tattoos. As far as we know, this is the first description of granulomatous reactions restricted to preexisting tattoos following BRAF inhibitor therapy.